A 867191
Alternative Names: A867191Latest Information Update: 24 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 26 Mar 1998 Phase-II clinical trials for Bacterial infections in USA (Parenteral)
- 15 Jun 1995 Three studies detailing the comparative antimicrobial activity of A 867191 have been added to the antimicrobial activity and pharmacodynamics sections ,,
- 26 Oct 1994 Preclinical development for Bacterial infections in USA (Parenteral)